AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7564934 — intervention group
Group type: EXPERIMENTAL
Intervention: Version I (n = 58) - trade-off with increasingly negative descriptions of outcomes of resuscitation
Number of subjects: 105
Study 7564934 — intervention group
Group type: EXPERIMENTAL
Intervention: Version II (n = 47) - trade-off with increasingly positive descriptions of outcomes of resuscitation
Number of subjects: 105
Study 2155650 — intervention group
Group type: EXPERIMENTAL
Intervention: Full series method of reading chest radiographs
Number of subjects: 33
Study 2155650 — intervention group
Group type: COMPARATOR
Intervention: Side by side pairs method
Number of subjects: 33
Study 2155650 — intervention group
Group type: COMPARATOR
Intervention: Two separate randomly ordered films method
Number of subjects: 33
Study 6772302 — intervention group
Group type: EXPERIMENTAL
Intervention: GTNO
Number of subjects: 10
Study 6772302 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10
Study 6772302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 6550482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole alone
Number of subjects: 80
Study 6550482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole plus tobramycin
Number of subjects: 80
Study 6550482 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 80
Study 6550482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole-treated patients
Number of subjects: 80
Study 6550482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin-containing sera
Number of subjects: 80
Study 6550482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole-plus-tobramycin-containing sera
Number of subjects: 80
Study 28117627 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based treatment for school refusal
Number of subjects: 112
Study 28117627 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 112
Study 27895297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive trial design with subgroup selection based on onset-to-randomization time
Number of subjects: 382
Study 27895297 — intervention group
Group type: COMPARATOR
Intervention: Fixed trial design
Number of subjects: 382
Study 27895297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive trial design with subgroup selection based on arterial occlusive lesion and time
Number of subjects: 382
Study 24347426 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day for 1 month
Number of subjects: 28
Study 24347426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (E₂) 4 mg/day for 1 month
Number of subjects: 28
Study 24347426 — intervention group
Group type: COMPARATOR
Intervention: GH treatment alone (0.5 mg/day) for 1 month
Number of subjects: 28
Study 24347426 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment with raloxifene (60 mg/day) for 1 month
Number of subjects: 28
Study 24347426 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment with estrogen (2 mg/day) for 1 month
Number of subjects: 28
Study 24347426 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene administration
Number of subjects: 28
Study 24347426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen administration
Number of subjects: 28
Study 22405235 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic training
Number of subjects: 60
Study 22405235 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic training with a secondary task (mental arithmetic task)
Number of subjects: 60
Study 21098449 — intervention group
Group type: EXPERIMENTAL
Intervention: varespladib 500 mg PO BID
Number of subjects: 144
Study 21098449 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144
Study 18295412 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic film (1-hour combat footage)
Number of subjects: 10
Study 18295412 — intervention group
Group type: COMPARATOR
Intervention: Neutral film (1-hour oil painting tutorial)
Number of subjects: 10
Study 18295412 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic film
Number of subjects: 10
Study 15698697 — intervention group
Group type: COMPARATOR
Intervention: Principal component analysis applied to kinematic and kinetic waveforms of lifting technique.
Number of subjects: 16
Study 14623668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling on an ergometer bicycle until the pulse rate reached a steady state level and a score of 14 to 17 on Borg's Ratio of Perceived Exertion scale
Number of subjects: 24
Study 14623668 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 24
Study 11025624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 259
Study 11025624 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 259
Study 11025624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyproheptadine and propranolol
Number of subjects: 259
Study 11025624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 9002796 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Antiseptic (LA)
Number of subjects: 25
Study 9002796 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol control rinse
Number of subjects: 25
Study 1335645 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of live attenuated hepatitis A vaccine at doses of 10(4), 10(5), 10(6), and 10(7) TCID50
Number of subjects: 0
Study 1335645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of live attenuated hepatitis A vaccine at doses of 10(6) and 10(7) TCID50
Number of subjects: 0
Study 1335645 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6363896 — intervention group
Group type: EXPERIMENTAL
Intervention: Human (semisynthetic) insulin
Number of subjects: 21
Study 6363896 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 21
Study 31038125 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic men (ALCM)
Number of subjects: 88
Study 31038125 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic women (ALCW)
Number of subjects: 88
Study 29493347 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 60
Study 29493347 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CP)
Number of subjects: 60
Study 27544023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed‐FP7 implant
Number of subjects: 238
Study 27544023 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt‐350 implant
Number of subjects: 238
Study 24549550 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program with minimal supervision (n=120)
Number of subjects: 232
Study 24549550 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n=112)
Number of subjects: 232
Study 22221551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 30
Study 22221551 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy with 75% glucose solution
Number of subjects: 30
Study 20929599 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine BDP, 100 μg, b.i.d.
Number of subjects: 14
Study 20929599 — intervention group
Group type: COMPARATOR
Intervention: Nonextrafine BDP, 250 μg, b.i.d.
Number of subjects: 14
Study 19100092 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs) for 3 months
Number of subjects: 74
Study 19100092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 19100092 — intervention group
Group type: EXPERIMENTAL
Intervention: Total recurrence rate
Number of subjects: 74
Study 16284568 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy electrode
Number of subjects: 24
Study 16284568 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous electrode
Number of subjects: 24
Study 12353945 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 4
Study 12353945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 10774084 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline studies prior to randomisation to antimalarial prophylactic regimens
Number of subjects: 705
Study 8869674 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (lungs deflated)
Number of subjects: 30
Study 8869674 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (static inflation with PEEP = 5 cmH2O and FIO2 = 1.0)
Number of subjects: 30
Study 8869674 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (static inflation with PEEP = 5 cmH2O and FIO2 = 0.21)
Number of subjects: 30
Study 1843523 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 16
Study 1843523 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 16
Study 6349608 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (150 mg/d)
Number of subjects: 20
Study 6349608 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg/d)
Number of subjects: 20
Study 6349608 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (100 mg/d) at low altitude
Number of subjects: 20
Study 6349608 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide
Number of subjects: 20
Study 28416515 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 67
Study 28416515 — intervention group
Group type: COMPARATOR
Intervention: Traditional IBS diet
Number of subjects: 67
Study 28247654 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for acute serous and purulent pyelonephritis
Number of subjects: 62
Study 25741619 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training with 0% load
Number of subjects: 0
Study 25741619 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training with 5% load
Number of subjects: 0
Study 25741619 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training with 10% load
Number of subjects: 0
Study 23927490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) about starting statins
Number of subjects: 103
Study 23927490 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 103
Study 20159716 — intervention group
Group type: EXPERIMENTAL
Intervention: General-epidural anesthesia combined with PCEA (GE group)
Number of subjects: 100
Study 20159716 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (G group)
Number of subjects: 100
Study 18575849 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 25
Study 18575849 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 25
Study 16183220 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (10mg per day)
Number of subjects: 53
Study 16183220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12532366 — intervention group
Group type: EXPERIMENTAL
Intervention: TTouch (5-min intervention)
Number of subjects: 93
Study 12532366 — intervention group
Group type: COMPARATOR
Intervention: No-touch control group
Number of subjects: 93
Study 10989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface laryngeal electromyography
Number of subjects: 10
Study 10989855 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular laryngeal electromyography
Number of subjects: 10
Study 8894360 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (AC)
Number of subjects: 292
Study 8894360 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam (TX)
Number of subjects: 292
Study 1797191 — intervention group
Group type: EXPERIMENTAL
Intervention: 773U82.HCl at doses ranging from 15 mg/m2 to 980 mg/m2
Number of subjects: 36
Study 1797191 — intervention group
Group type: EXPERIMENTAL
Intervention: 773U82.HCl at 980 mg/m2
Number of subjects: 36
Study 1797191 — intervention group
Group type: EXPERIMENTAL
Intervention: 773U82.HCl at 720 mg/m2
Number of subjects: 36
Study 1797191 — intervention group
Group type: EXPERIMENTAL
Intervention: 773U82.HCl infusion duration increase
Number of subjects: 36
Study 1797191 — intervention group
Group type: EXPERIMENTAL
Intervention: 773U82.HCl
Number of subjects: 36
Study 1797191 — intervention group
Group type: EXPERIMENTAL
Intervention: 773U82.HCl pharmacokinetic studies
Number of subjects: 36
Study 6679239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cost education and cost audits
Number of subjects: 0
Study 6679239 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty chart review
Number of subjects: 0
Study 6679239 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30600265 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic Sequencing (GS)
Number of subjects: 493
Study 30600265 — intervention group
Group type: COMPARATOR
Intervention: Newborn Screening (NBS)
Number of subjects: 493
Study 30669797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 81
Study 30669797 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg)
Number of subjects: 81
Study 30669797 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml normal saline)
Number of subjects: 81
Study 26012474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil administration after primary PCI
Number of subjects: 32
Study 23719148 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Tool - Pocket reminder card with preventive medication guidelines
Number of subjects: 213
Study 23719148 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Tool - Monthly team feedback reports
Number of subjects: 213
Study 23719148 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Tool - Refrigerator magnet patient reminder card
Number of subjects: 213
Study 23719148 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison group (no intervention)
Number of subjects: 213
Study 20499312 — intervention group
Group type: EXPERIMENTAL
Intervention: Model I (tumours with potential for progression)
Number of subjects: 2310
Study 20499312 — intervention group
Group type: EXPERIMENTAL
Intervention: Model II (tumours without potential for progression)
Number of subjects: 2310
Study 20499312 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed prevalence from ERSPC-Rotterdam
Number of subjects: 2310
Study 20499312 — intervention group
Group type: COMPARATOR
Intervention: ERSPC-Rotterdam data
Number of subjects: 2310
Study 19141764 — intervention group
Group type: COMPARATOR
Intervention: Supervised treadmill exercise
Number of subjects: 156
Study 19141764 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity resistance training
Number of subjects: 156
Study 17424755 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier cessation of desflurane supply
Number of subjects: 30
Study 17424755 — intervention group
Group type: COMPARATOR
Intervention: Desflurane supply continued until the end of the operation
Number of subjects: 30
Study 15383254 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formula of TongxieYaofang and clostridium butyricum (Cb) for four weeks
Number of subjects: 60
Study 15383254 — intervention group
Group type: COMPARATOR
Intervention: Clostridium butyricum (Cb) for four weeks
Number of subjects: 60
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin + clindamycin
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: tobramycin + clindamycin
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: meropenem
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: aztreonam + clindamycin
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: cefoxitin
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotetan
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: moxalactam
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotaxime + metronidazole
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanic acid
Number of subjects: 79
Study 11485888 — intervention group
Group type: EXPERIMENTAL
Intervention: quinolone studies
Number of subjects: 79
Study 9699364 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials published in English
Number of subjects: 229
Study 9699364 — intervention group
Group type: COMPARATOR
Intervention: Trials published in other languages (French, German, Italian, Spanish)
Number of subjects: 229
Study 8626882 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining ambulatory
Number of subjects: 29
Study 8626882 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining supine for 8 hours
Number of subjects: 29
Study 8626882 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 10:00 PM with a standardized meal, subjects remaining supine for 8 hours
Number of subjects: 29
Study 8626882 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 10:00 PM on an empty stomach, subjects remaining supine for 8 hours
Number of subjects: 29
Study 8626882 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of dosing
Number of subjects: 29
Study 1972124 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg
Number of subjects: 10
Study 1972124 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 10
Study 1972124 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 300 mg
Number of subjects: 10
Study 1972124 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 600 mg
Number of subjects: 10
Study 1972124 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1972124 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate (all dosages)
Number of subjects: 10
Study 352976 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine treatment
Number of subjects: 0
Study 352976 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31346900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuncali et al. formula
Number of subjects: 80
Study 31346900 — intervention group
Group type: COMPARATOR
Intervention: Hong‐yun Liu et al. formula
Number of subjects: 80
Study 31590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated kangaroo mother care
Number of subjects: 8402
Study 31590989 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 8402
Study 26350524 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI)
Number of subjects: 117
Study 26350524 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 117
Study 26350524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WBI and APBI
Number of subjects: 117
Study 23376852 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (group I)
Number of subjects: 62
Study 23376852 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive treatment (control group II)
Number of subjects: 62
Study 21757334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 127
Study 21757334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 127
Study 21757334 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 127
Study 21757334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (both doses)
Number of subjects: 127
Study 19968384 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + pharmacotherapy
Number of subjects: 42
Study 19968384 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 42
Study 16364575 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of trimegestone (TMG)
Number of subjects: 487
Study 16364575 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone acetate (NETA)
Number of subjects: 487
Study 15365734 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg/OD for 6 weeks
Number of subjects: 160
Study 15365734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10751747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 45
Study 10751747 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate 400 mg
Number of subjects: 45
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 35
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound angiography with intraarterial CO2 microbubbles (USAG)
Number of subjects: 35
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography during arterial portography (CTAP)
Number of subjects: 35
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry using QB monoclonal antibody
Number of subjects: 35
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic findings
Number of subjects: 35
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in portal perfusion
Number of subjects: 35
Study 9365041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinomas with fatty metamorphosis
Number of subjects: 35
Study 1562863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10, 20 or 30 mg/day of oral fluphenazine hydrochloride
Number of subjects: 41
Study 3909333 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus tobramycin
Number of subjects: 45
Study 3909333 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus cloxacillin
Number of subjects: 45
Study 3909333 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam plus tobramycin
Number of subjects: 45